Ðǿմ«Ã½

    Advertisement

    We only need a few more clicks to be able to show the most read stories for this topic. Take a look at the latest headlines below and help us out by clicking on what you find interesting!

    In the last 7 days
    Cosmopolitan US18:04 9-Oct-26
    Gizmodo15:46 9-Oct-26
    The Westmeath Independent10:27 9-Oct-26
    The Motley Fool22:40 8-Oct-26
    Medical Daily19:31 8-Oct-26
    Business Wire (Press Release)08:07 8-Oct-26
    Zacks18:52 7-Oct-26
    The Motley Fool15:50 7-Oct-26
    Chemistry World Magazine04:59 7-Oct-26
    The Motley Fool20:30 6-Oct-26
    Zacks10:02 6-Oct-26
    The Motley Fool09:18 6-Oct-26
    Medical Daily05:47 6-Oct-26
    Business Wire (Press Release)12:13 5-Oct-26
    Diabetes UK09:24 5-Oct-26
    University of Copenhagen07:22 5-Oct-26
    Business Wire (Press Release)07:06 5-Oct-26
    The Korea Herald22:26 4-Oct-26
    The Motley Fool17:29 4-Oct-26
    In the last month
    Medical Daily08:40 3-Oct-26
    Novo Nordisk17:15 2-Oct-26
    The Motley Fool16:27 2-Oct-26
    Medical Daily14:56 2-Oct-26
    Medical Daily14:56 2-Oct-26
    Anthropic13:04 2-Oct-26
    The Motley Fool12:23 2-Oct-26
    Proactive Investors (US)02:38 2-Oct-26
    RTT News13:34 1-Oct-26
    Medical Daily11:28 1-Oct-26
    Proactive Investors (UK)06:16 1-Oct-26
    Medical Daily21:25 30-Sep-26
    Korea Biomedical Review21:01 30-Sep-26
    The Motley Fool19:33 30-Sep-26
    The Motley Fool17:31 30-Sep-26
    The Economic Times15:01 30-Sep-26
    News-Medical.Net13:22 30-Sep-26
    The Motley Fool10:34 30-Sep-26
    Manufacturing Chemist10:29 30-Sep-26
    Benzinga10:29 30-Sep-26
    The Business Standard10:11 30-Sep-26
    Broad Institute of MIT and Harvard09:08 30-Sep-26
    Novo Nordisk08:48 30-Sep-26
    NewsMax07:44 30-Sep-26
    Korea Biomedical Review01:00 30-Sep-26
    The Motley Fool23:52 29-Sep-26
    Zacks18:50 29-Sep-26
    ScienceNorway18:05 29-Sep-26
    Law36012:03 29-Sep-26
    ShareCast08:09 29-Sep-26
    RTT News07:17 29-Sep-26
    Novo Nordisk06:07 29-Sep-26
    Simply Wall St06:04 29-Sep-26
    Anadolu Agency04:50 29-Sep-26
    Hong Kong Standard02:58 29-Sep-26
    European Pharmaceutical Review05:21 28-Sep-26
    Business Wire (Press Release)02:03 28-Sep-26
    The Motley Fool18:26 27-Sep-26
    The Motley Fool12:23 26-Sep-26
    Simply Wall St22:00 25-Sep-26
    IBTimes (US)19:07 25-Sep-26
    The Motley Fool17:13 25-Sep-26
    Law36016:35 25-Sep-26
    HumanProgress14:22 25-Sep-26
    Mint11:26 25-Sep-26
    Zacks10:02 25-Sep-26
    The Motley Fool06:32 25-Sep-26
    ShareCast05:41 25-Sep-26
    Law36020:45 24-Sep-26
    A&O Shearman (Press Release)19:52 24-Sep-26
    The Motley Fool17:28 24-Sep-26
    JD Supra15:23 24-Sep-26
    Sweden Herald14:20 24-Sep-26
    The Hindu Business Line10:25 24-Sep-26
    The Times of India10:16 24-Sep-26
    University of Copenhagen04:21 24-Sep-26
    Zacks18:53 23-Sep-26
    BioWorld13:40 23-Sep-26
    Fortune07:16 23-Sep-26
    azfamily.com, Arizona17:51 22-Sep-26
    Florida Attorney General (Press Releases)17:06 22-Sep-26
    view more headlines
    9 Oct 18:04

    About our Novo Nordisk news

    Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

    Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

    Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

    In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

    Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

    As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our Ðǿմ«Ã½ feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.